Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Catarina Craveiro, a biomedical research technician from Lisbon, had been hobbled by lower back pain from scoliosis since ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...

Atogepant vs placebo for the preventative treatment of migraine alleviated migraine symptoms across 3 clinical trials on day 1.

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Craveiro from Lisbon had scoliosis since childhood, but now, she is not just free from any pain, but has become a competitive ...

CNM-Au8 prolonged survival for people with ALS relative to those who received the investigational treatment zilucoplan or a ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.